• Ionis Pharmaceuticals recently announced that the FDA accepted for Priority Review its New Drug Application for zilganersen, an RNA-targeted therapy for Alexander disease, with a Prescription Drug User Fee Act target action date set for September 22, 2026, following pivotal data showing clinically meaningful stabilization of gait and favorable safety.
• An interesting angle for investors is that zilganersen carries multiple expedited and rare-disease designations, highlighting regulatory recognition of its potential impact in a small but severely affected patient population.
• Next, we’ll examine how the new US$40,000 Tryngolza pricing and positive analyst reaction may reshape Ionis’ investment narrative.

Uncover the next big thing…